Health & Fitness
Thu, October 4, 2012
SEATTLE--([ BUSINESS WIRE ])--October 3, 2012a" Dendreon Corporation (NASDAQ:DNDN) today announced the company will be presenting at the MD Becker Partnersa 3rd Annual Cancer Immunotherapy: A Long-Awaited Reality conference taking place from 8:00 a.m. to 6:30 p.m. EDT on October 4, 2012, at the New York Academy of Medicine in New York.
"Cancer Vaccines - Past, Present and Future"
Mark W. Frohlich, MD, executive vice president of research and development and chief medical officer at Dendreon, will provide an overview of PROVENGE (sipuleucel-T), the first FDA-approved autologous cellular immunotherapy for cancer. The presentation is expected to begin at 3:00 p.m. EDT.
A live and archived webcast of the company's presentation at the conference, hosted by MD Becker Partners LLC, will be available at [ www.regonline.com/mdb2012 ].
Dr. Frohlich will also participate in two panel sessions:
- aWhere Does Immunotherapy Fit into the Prostate Cancer Landscape?a - 9:00 a.m. EDT
- aCancer Vaccines - Past, Present and Futurea - 11:00 a.m. EDT
About the 3rd Annual Cancer Immunotherapy: A Long-Awaited Reality Conference
"Cancer Immunotherapy: A Long Awaited Reality" is a unique, single-day conference event that unites founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of cancer immunotherapy.
AboutDendreon
Dendreon Corporationis a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE (sipuleucel-T), was approved by the FDA inApril 2010. Dendreonis exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered inSeattle, Washington,and is traded on theNASDAQ Global Marketunder the symbol DNDN. For more information about the Company and its programs, visit [ http://www.dendreon.com ].
